Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 60760-560

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 60760-560). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rabe-str (Rabe Str)

Chemical structure diagram of rabeprazole sodium, showing its heterocyclic rings and side chains, consistent with the active ingredient rabeprazole sodium.*

FDA Label Image

Rabe-str2 (Rabe Str2)

A line graph displaying mean heartburn scores over time by study day for a clinical trial with three groups: placebo, rabeprazole 10 mg, and rabeprazole 20 mg. The y-axis shows mean score ranging from 0 (none) to 4 (very severe), and the x-axis shows study days from -14 to 28. The graph shows symptom scores before and after treatment start (day 0).*

FDA Label Image

Rabe-str3 (Rabe Str3)

A line graph showing mean heartburn scores over a 28-day study period comparing Rabeprazole Sodium 20 mg tablets to placebo. The x-axis represents study days from -14 to 28, and the y-axis represents mean heartburn scores from 0 (None) to 4 (Very Severe). Two lines indicate that heartburn severity decreases over time, with Rabeprazole Sodium showing a greater reduction after day 0 compared to placebo.*

FDA Label Image

Rabe-str4 (Rabe Str4)

A line graph comparing heartburn scores over 28 study days between two groups: one receiving placebo (n=58) and the other receiving Rabeprazole Sodium 20 mg (n=59). The y-axis represents mean heartburn scores from 0 (none) to 4 (very severe), while the x-axis shows study days from -14 to 28. The graph shows a notable decrease in heartburn scores after day 0 for both groups, with Rabeprazole group scores generally lower than placebo.*

FDA Label Image

Rab (Rabeprazole 60760 560 30)

Label for Rabeprazole Sodium delayed-release tablets, 20 mg, with a quantity of 30 tablets. The label indicates the product is manufactured by Alkem Laboratories Ltd., Mumbai, India, and packaged by St. Mary's Medical Park Pharmacy in Oro Valley, AZ. The label includes NDC 60760-560-30 and notes store at controlled room temperature 15-30°C (59-86°F). Lot number and expiration date are shown as unknown or placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.